These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25615583)

  • 1. A path to eradication of hepatitis C in low- and middle-income countries.
    Graham CS; Swan T
    Antiviral Res; 2015 Jul; 119():89-96. PubMed ID: 25615583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can hepatitis C virus infection be eradicated in people who inject drugs?
    Grebely J; Dore GJ
    Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C eradication: A long way to go.
    Waheed Y
    World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can hepatitis C be eradicated in the United States?
    Edlin BR; Winkelstein ER
    Antiviral Res; 2014 Oct; 110():79-93. PubMed ID: 25110202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
    Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV transmission in industrialized countries and resource-constrained areas.
    Thursz M; Fontanet A
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):28-35. PubMed ID: 24080775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas.
    Lemoine M; Thursz M
    Semin Liver Dis; 2014 Feb; 34(1):89-97. PubMed ID: 24782262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
    Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
    Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment as prevention: evidence, feasibility, and challenges.
    Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ
    Lancet Gastroenterol Hepatol; 2016 Dec; 1(4):317-327. PubMed ID: 28404202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards hepatitis C eradication from the HIV-infected population.
    Barreiro P; Fernandez-Montero JV; de Mendoza C; Labarga P; Soriano V
    Antiviral Res; 2014 May; 105():1-7. PubMed ID: 24534673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.
    Grebely J; Matthews GV; Lloyd AR; Dore GJ
    Clin Infect Dis; 2013 Oct; 57(7):1014-20. PubMed ID: 23728143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus therapeutic development: in pursuit of "perfectovir".
    Dore GJ; Feld JJ
    Clin Infect Dis; 2015 Jun; 60(12):1829-36. PubMed ID: 25761867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future HCV therapy: do we still need other anti-HCV drugs?
    Petta S; Craxì A
    Liver Int; 2015 Jan; 35 Suppl 1():4-10. PubMed ID: 25529081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.
    Bennett H; Gordon J; Jones B; Ward T; Webster S; Kalsekar A; Yuan Y; Brenner M; McEwan P
    Eur J Health Econ; 2017 Nov; 18(8):1001-1011. PubMed ID: 27803989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.